

Notes to the Consolidated Financial Statements for the Year Ended 30 June 2014

NOTE 27: BENITEC BIOPHARMA LIMITED PARENT COMPANY INFORMATION

	2014 \$	Parent Entity 2013 \$
ASSETS		
Current assets	34,386,167	1,478,422
Non-current assets	181,547	48,999
TOTAL ASSETS	34,567,714	1,527,421
LIABILITIES		
Current liabilities	1,311,608	1,165,652
Non-current liabilities	-	-
TOTAL LIABILITIES	1,311,608	1,165,652
NET ASSETS	33,256,106	361,769
EQUITY		
Contributed equity	129,185,675	89,609,248
Share based payments reserve	2,096,818	1,591,702
Accumulated losses	(98,026,387)	(90,839,181)
TOTAL EQUITY	33,256,106	361,769
FINANCIAL PERFORMANCE		
Loss for the year	(7,037,206)	(4,885,852)
Other comprehensive income	-	-
TOTAL COMPREHENSIVE INCOME	(7,037,206)	(4,885,852)

Contingent liabilities

The parent entity had no contingent liabilities as at 30 June 2014 (2013: nil), other than the contingent liabilities described in note 22.

Capital commitments

The parent entity has no capital commitments as at 30 June 2014 (2013: nil).

Significant accounting policies

The accounting policies of the parent are consistent with those of the consolidated entity (Note 1)